Corcept Therapeutics (CORT) officer awarded stock options on 140,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics reported that officer Sean Maduck received a grant of stock options covering 140,000 shares of the company’s stock. The award was recorded as an acquisition of derivative securities at no cash cost on the grant date.

According to the terms, these options vest in equal installments on each monthly anniversary of February 27, 2026 over a four-year period, and vesting requires Mr. Maduck’s continued service through each vesting date. Following this grant, he is shown as holding stock options for 140,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Maduck Sean

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	140,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 140,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 06:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maduck Sean

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$35.7	02/27/2026		A		140,000		⁽¹⁾	02/27/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Corcept Therapeutics (CORT) report for Sean Maduck?

Corcept Therapeutics reported that officer Sean Maduck received a grant of stock options for 140,000 shares. The transaction is classified as an acquisition of derivative securities, increasing his directly held stock options to 140,000 shares following the grant.

How many Corcept Therapeutics (CORT) shares are covered by Sean Maduck’s new stock option grant?

The new stock option grant to Sean Maduck covers 140,000 shares of Corcept Therapeutics common stock. This entire amount is reflected as stock options he holds directly following the transaction, according to the Form 4 insider filing data provided.

What type of security did Sean Maduck acquire in the Corcept Therapeutics (CORT) Form 4?

Sean Maduck acquired a stock option, described as a “Stock Option (right to buy)” Corcept Therapeutics shares. This is a derivative security giving the right to purchase 140,000 shares, rather than an immediate purchase of common stock itself.

When was Sean Maduck’s Corcept Therapeutics (CORT) stock option grant dated?

The stock option grant to Sean Maduck is dated February 27, 2026. This date is used as the reference point for the vesting schedule, with the options vesting in monthly installments starting from each monthly anniversary of that date.

How do Sean Maduck’s Corcept Therapeutics (CORT) options vest over time?

The options vest ratably in equal installments on each monthly anniversary of February 27, 2026 over four years. Vesting is conditioned on his continued service through each vesting date, meaning unvested portions depend on ongoing employment.

Does the Corcept Therapeutics (CORT) filing show Sean Maduck buying or selling stock?

The filing does not show open-market buying or selling of common stock by Sean Maduck. It reports an acquisition of stock options as a grant or award, recorded as a derivative security transaction rather than a cash stock purchase or sale.